Renew the paradigm. Optimize our therapy.
The "Choosing Wisely Canada" toolkit promoting limitation of Free T3 and Free T4 testing has been the food for some meme refutations. Choosing Wisely Canada. (n.d.). Toolkit: Less is More with T3 & T4. Retrieved December 30, 2018, from https://choosingwiselycanada.org/perspective/toolkit-t4-t3/ Recently, we've focused on their Table 2 which outlines situations they recommend NOT to order …
Continue reading MEMES: Against Table 2 in the “Choosing Wisely Canada” T3 & T4 toolkit
UBIQUITINATION: This is the "Glass ceiling" of T4 monotherapy -- there is a biological limit on how much T3 you can get out of treatment with T4 thyroid hormone alone (Synthroid, levothyroxine). The enzyme responsible for the majority of our body's T4-T3 conversion is Deiodinase Type 2 (D2), and it does its job of conversion …
Continue reading Ubiquitination: The glass ceiling of T4 monotherapy
Choosing Wisely Canada, together with the Canadian Society for Endocrinology and Metabolism, have collaborated on a harmful toolkit to reduce Free T3 and Free T4 hormone testing in order to save money. As you can see in their Table 2 from page 9 of their toolkit, they want to prevent T3 and T4 testing in …
Continue reading Our response to Choosing Wisely’s harmful Table 2
We have compiled a bibliography on Atrophic Thyroiditis and the TSHR antibody that is continually under development. 127 items exist in the bibliography as of December 2018 Screenshot The database is in a Google Spreadsheet. Click this link to access : https://docs.google.com/spreadsheets/d/1MlwMCGUnEF_ptUE9S9znMnN5oNkuAqA2fUNxvD2zrRw/edit?usp=sharing
Why have clinical trials of T3-T4 combination therapy failed to show significant benefit? Hoermann et al explain that the trials and the meta-analyses exhibit a fundamental problem with research methodology and a fundamental misunderstanding of thyroid hormone relationships that results in statistical errors. SOURCE Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. …
Continue reading Simpson’s paradox: Hoermann et al explain why T4-T3 therapy trials are faulty
